A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable eventual development of SC formulation. It will assess how much belantamab is absorbed and how long it stays in the blood as well as assess whether it is safe and tolerated well by participants.

NCT Number	NCT07742527
Lead Sponsor	GlaxoSmithKline
Conditions	Multiple Myeloma
Enrollment	22 participants
Start Date	2026-10-16
Primary Completion	2027-08-05 (estimated)
Study Completion	2030-03-18 (estimated)
Updated on ClinicalTrials.gov	2026-08-03